Andlauer Healthcare Group (AND) AI Stock Analysis

• Market Cap: $2.15B
• Dividend Yield: 0.86%
• Average Volume (3M): 33.27K
• Price to Earnings (P/E): 32.0
• Beta (1Y): 0.35
• Revenue Growth: 0.34%
• EPS Growth: 10.40%
• Country: CA
• Employees: 2,380
• Sector: Industrials
• Sector Strength: 72
• Industry: Integrated Freight & Logistics
• EPS (TTM): 0.33
• Shares Outstanding: 18,342,255
• 10 Day Avg. Volume: 44,468
• 30 Day Avg. Volume: 33,269
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 3.38
• Enterprise Value/Gross Profit: 14.77
• Enterprise Value/Ebitda: 12.96
• 1Y Price Target: $54.64
• Price Target Upside: -0.60% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: C$56.00 ▲(1.87% Upside)

The overall stock score of 60 reflects a balance of solid financial performance and operational efficiency against the backdrop of negative revenue and cash flow growth. Technical indicators suggest mild upward momentum, but valuation metrics indicate the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.

Positive Factors

Business Model Strength

The company's focus on healthcare logistics provides a stable revenue base, leveraging specialized services that meet stringent regulatory requirements, ensuring long-term demand.

Operational Efficiency

Strong operational efficiency and healthy margins indicate effective management and cost control, supporting sustainable profitability and competitive advantage.

Balance Sheet Health

A manageable debt-to-equity ratio reflects prudent financial management, ensuring financial stability and flexibility to support future growth initiatives.

Negative Factors

Negative Revenue Growth

Declining revenue growth can signal weakening market demand or competitive pressures, potentially impacting long-term business sustainability and market position.

Free Cash Flow Concerns

Negative free cash flow growth may limit the company's ability to reinvest in its operations or pursue strategic opportunities, affecting long-term growth prospects.

Profit Margin Decline

A declining profit margin could indicate rising costs or pricing pressures, which may erode profitability if not addressed, impacting long-term financial health.

Andlauer Healthcare Group Business Overview & Revenue Model

Company Description

Andlauer Healthcare Group Inc. (AND) is a leading provider of healthcare logistics and specialized transportation services in North America. The company operates through two primary sectors: logistics and transportation, offering services that include warehousing, distribution, and supply chain management tailored specifically for the pharmaceutical and healthcare industries. AND's core products and services are designed to ensure the safe and efficient delivery of medical products, including temperature-sensitive items, to healthcare providers and patients.

How the Company Makes Money

Andlauer Healthcare Group generates revenue through multiple key streams, primarily from its logistics and transportation services. The company earns money by providing warehousing and distribution solutions for pharmaceutical and healthcare products, which often involve complex supply chain requirements. Additionally, AND has a significant revenue stream from specialized transportation services, including the delivery of temperature-controlled products. The company may also engage in partnerships with pharmaceutical companies, hospitals, and other healthcare entities, which can enhance its market reach and operational efficiency. Furthermore, the growing demand for healthcare logistics, driven by the increasing complexity of drug distribution and the rise of e-commerce in the healthcare sector, contributes to the company's earnings potential.

Andlauer Healthcare Group Financial Statement Overview

Summary

Andlauer Healthcare Group demonstrates strong financial health with consistent revenue growth, robust profitability, and a sound balance sheet. Despite an increase in debt levels, the company efficiently converts income into cash, supporting its operations and growth.

Income Statement

The company has shown consistent revenue growth with the TTM revenue at CAD 655.43 million, up from CAD 650.48 million in the previous year. Gross profit margin remains stable at approximately 22.9% in the TTM. The net profit margin has improved to 10.64% in the TTM, reflecting stronger profitability. EBIT and EBITDA margins are robust at 14.38% and 26.06% respectively, indicating efficient operational management. The overall trajectory is positive with healthy profitability metrics.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.41 in the TTM, indicating moderate leverage. Return on Equity (ROE) is healthy at 15.72%, showcasing effective utilization of equity. The equity ratio stands at 62.31%, suggesting a strong capital structure with adequate equity to cover liabilities. The company's balance sheet is solid, although the increasing debt levels in the TTM warrant monitoring.

Cash Flow

The company exhibits strong cash flow generation with TTM operating cash flow of CAD 124.24 million and free cash flow of CAD 105.79 million. Free cash flow growth is modest at 1.7% compared to the previous year, but the operating cash flow to net income ratio is a robust 1.78, indicating excellent cash conversion efficiency. The cash flow position is solid, providing flexibility for future investments or debt repayment.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	655.43M	650.48M	647.95M	648.42M	440.12M	314.34M
Gross Profit	149.89M	147.20M	147.48M	158.85M	110.75M	79.55M
EBITDA	170.76M	166.72M	166.96M	175.07M	154.91M	79.20M
Net Income	69.77M	64.47M	66.14M	76.28M	89.95M	37.71M
Balance Sheet
Total Assets	712.63M	696.92M	682.43M	712.46M	644.17M	252.80M
Cash, Cash Equivalents and Short-Term Investments	44.10M	40.48M	59.74M	65.86M	24.99M	30.15M
Total Debt	182.60M	181.21M	127.90M	163.29M	187.25M	129.61M
Total Liabilities	268.57M	265.78M	212.86M	271.47M	292.05M	158.47M
Stockholders Equity	444.06M	431.13M	469.57M	440.99M	352.12M	94.33M
Cash Flow
Free Cash Flow	105.79M	104.02M	78.83M	109.17M	74.42M	45.56M
Operating Cash Flow	124.24M	124.40M	104.42M	137.13M	84.09M	51.00M
Investing Cash Flow	-24.23M	-18.86M	-23.85M	-45.56M	-183.38M	-20.37M
Financing Cash Flow	-124.86M	-126.24M	-86.18M	-51.59M	93.89M	-19.20M

Andlauer Healthcare Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 54.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AND, the sentiment is Positive. The current price of 54.97 is above the 20-day moving average (MA) of 53.25, above the 50-day MA of 53.14, and above the 200-day MA of 49.36, indicating a bullish trend. The MACD of 0.54 indicates Negative momentum. The RSI at 72.83 is Negative, neither overbought nor oversold. The STOCH value of 85.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AND.

Andlauer Healthcare Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CJT	65 Neutral	$1.25B	8.72	16.75%	2.02%	7.71%	3170.43%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
AND	60 Neutral	$2.15B	31.98	15.64%	0.86%	0.34%	10.40%
TTNM	49 Neutral	C$59.19M	-2.34	-24.17%	6.30%	2.28%	-1613.54%

Andlauer Healthcare Group Corporate Events

Andlauer Healthcare Declares Q3 Dividend

Andlauer Healthcare Group Inc. has announced a third-quarter dividend of $0.12 per share for both subordinate and multiple voting shares, payable on October 15, 2025. This announcement reflects AHG’s ongoing commitment to delivering value to its shareholders while reinforcing its strong position in the healthcare supply chain management industry.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$57.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

Andlauer Healthcare Group’s Q2 Results and UPS Acquisition

Andlauer Healthcare Group Inc. (AHG) is a prominent supply chain management company specializing in third-party logistics and specialized transportation solutions for the healthcare sector, offering services across Canada and the contiguous United States.

Andlauer Healthcare Group Reports Q2 2025 Results Amid Acquisition by UPS

Andlauer Healthcare Group reported a decrease in revenue for Q2 2025, primarily due to challenges in its US-based truckload businesses and the deconsolidation of a packaging subsidiary. Despite these challenges, the company maintained its EBITDA margin within the target range. The company is set to be acquired by UPS in an all-cash transaction valued at approximately $2.2 billion, with the transaction expected to close in the second half of the year, pending regulatory approval.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$42.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.